Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

26.93 +0.94 (+3.62%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist

Price and Volume

Volume	2,047,958
Open	26.09
Bid (Size)	26.82 (100)
Ask (Size)	27.00 (100)
Prev. Close	25.99
Today's Range	25.69 - 27.02
52wk Range	13.53 - 36.44
Shares Outstanding	79,199,501
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933 ↗

February 01, 2026

Beam Therapeutics specializes in gene-editing medicines, and recently, the company's Senior Vice President edited out thousands of shares from her portfolio.

Via The Motley Fool

Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗

January 29, 2026

Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits.

Via Stocktwits

Performance

YTD	-0.8%	-0.8%
1 Month	-20.1%	-20.1%
3 Month	+23.1%	+23.1%
6 Month	+53.7%	+53.7%
1 Year	+0.3%	+0.3%

More News

BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise ↗

January 12, 2026

Via Stocktwits

Top stock movements in today's session. ↗

January 12, 2026

Via Chartmill

Is Beam Therapeutics Gaining or Losing Market Support? ↗

September 22, 2025

Via Benzinga

What Does the Market Think About Beam Therapeutics? ↗

August 25, 2025

Via Benzinga

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

January 11, 2026

From Beam Therapeutics

Via GlobeNewswire

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Via MarketMinute

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

December 06, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics (BEAM) Earnings Transcript ↗

November 27, 2025

Via The Motley Fool

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

November 12, 2025

From Beam Therapeutics

Via GlobeNewswire

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

Via TokenRing AI

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗

November 04, 2025

Via Benzinga

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

November 04, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Beam Therapeutics

Via GlobeNewswire

WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗

October 20, 2025

Via Benzinga

Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts

October 09, 2025

Via MarketMinute

Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves ↗

October 08, 2025

Via Benzinga

Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors

October 04, 2025

Via MarketMinute

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Via Benzinga

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

Via MarketMinute

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

August 25, 2025

From Beam Therapeutics

Via GlobeNewswire

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease ↗

August 15, 2025

Via Benzinga

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

August 14, 2025

From Beam Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Beam Therapeutics Inc. - Common Stock publicly traded?

Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Beam Therapeutics Inc. - Common Stock trade on?

Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?

The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market

What is the current price of Beam Therapeutics Inc. - Common Stock?

The current price of Beam Therapeutics Inc. - Common Stock is 26.93

When was Beam Therapeutics Inc. - Common Stock last traded?

The last trade of Beam Therapeutics Inc. - Common Stock was at 02/12/26 04:00 PM ET

What is the market capitalization of Beam Therapeutics Inc. - Common Stock?

The market capitalization of Beam Therapeutics Inc. - Common Stock is 2.13B

How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?

Beam Therapeutics Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.